Information Provided By: 
Fly News Breaks for March 8, 2016
BMRN
Mar 8, 2016 | 06:34 EDT
Baird analyst Michael Ulz upgraded BioMarin Pharmaceutical to Outperform after assuming coverage of the name. The company is a leader in the orphan disease space with a "strong diversified base business and a robust pipeline," Ulz tells investors in a research note. The analyst believes current share levels provide an attractive investment opportunity. He raised his price target for the stock to $110 from $100. The drugmaker closed yesterday up $1.55 to $88.22 after Goldman Sachs upgraded the shares to Conviction Buy from Buy.
News For BMRN From the Last 2 Days
